LivaNova/$LIVN
1D1W1MYTD1Y5YMAX
About LivaNova
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
- Ticker
- $LIVN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,300
- Headquarters
- Gloucester, United Kingdom
- Website
- www.livanova.com
LivaNova Metrics
BasicAdvanced
$4.5B
23.95
$3.40
0.87
-
Price and volume
Market cap
$4.5B
Beta
0.87
52-week high
$85.76
52-week low
$48.82
Average daily volume
663K
Financial strength
Current ratio
1.45
Quick ratio
1.079
Long term debt to equity
25.622
Total debt to equity
26.556
Interest coverage (TTM)
6.29%
Profitability
EBITDA (TTM)
267.838
Gross margin (TTM)
68.26%
Net profit margin (TTM)
12.82%
Operating margin (TTM)
14.78%
Effective tax rate (TTM)
-76.97%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
5.23%
Return on equity (TTM)
15.40%
Valuation
Price to earnings (TTM)
23.951
Price to revenue (TTM)
3.03
Price to book
3.38
Price to tangible book (TTM)
13.63
Price to free cash flow (TTM)
30.07
Free cash flow yield (TTM)
3.33%
Free cash flow per share (TTM)
2.71
Growth
Revenue change (TTM)
12.39%
Earnings per share change (TTM)
-187.47%
3-year revenue growth (CAGR)
10.70%
3-year earnings per share growth (CAGR)
23.36%
What the Analysts think about LivaNova
Analyst ratings (Buy, Hold, Sell) for LivaNova stock.
LivaNova Financial Performance
Revenues and expenses
LivaNova Earnings Performance
Company profitability
LivaNova News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.